Macrogol (Polyethylene Glycol) for Constipation in Children
Polyethylene glycol (PEG/macrogol) is safe and effective for treating constipation in children of all ages, including infants under 2 years, with a recommended maintenance dose of approximately 0.7-0.8 g/kg/day.
Dosing by Age Group
Infants Under 18 Months
For infants younger than 18 months, the recommended maintenance dose is 0.78 g/kg/day (range 0.26-1.26 g/kg/day) 1. This dose has been shown to relieve constipation in 97.6% of patients with minimal side effects 1. The evidence demonstrates similar safety and efficacy profiles to older children, though systematic reviews note that optimal dosing regimens for infants under 24 months remain variable across studies, ranging from 0.45-1.1 g/kg/day for PEG 3350 2.
Children Over 18 Months
For older children, maintenance dosing of 0.7 g/kg/day is effective 3. While lower doses (0.3 g/kg/day) can achieve treatment success, they require more frequent dose adjustments and result in lower parental satisfaction 3.
Adolescents and Adults (17+ years)
The standard adult dose is 17 g once daily mixed in 4-8 ounces of beverage 4. This dose should not be used for more than 7 days without physician guidance for over-the-counter use 4.
Treatment Approach
Initial Management
- Start with 0.7-0.8 g/kg/day for maintenance therapy in children
- Ensure powder is fully dissolved before drinking 4
- Can be mixed in cold, hot, or room temperature beverages 4
- Do not combine with starch-based thickeners 4
Disimpaction (Fecal Impaction)
When fecal impaction is present, higher doses of 1.0-1.5 g/kg/day for 3 days are effective, achieving disimpaction in 95% of children 5. These higher doses are significantly more effective than lower doses (0.25-0.5 g/kg/day) for clearing impaction 5.
Duration of Therapy
- PEG can be used safely for extended periods (≥6 months to 18+ months) 6
- Mean duration in clinical practice is approximately 18.6 months without need for dose adjustment due to weight gain 6
- Long-term use normalizes bowel movements and improves clinical symptoms without serious adverse events 6
Safety Profile
PEG is remarkably safe across all pediatric age groups, including infants 1. Common adverse effects are:
- Transient diarrhea (13%) - resolves with dose adjustment 1, 5
- Bloating (18%) - more common with higher doses 5
- Abdominal cramping (5%) 5
- Increased gas 1
Critical safety point: No clinically significant electrolyte changes occur with PEG use 5. Gastrointestinal adverse events decrease markedly after the first week of treatment 7.
Alternative for Infants
For infants with constipation, fruit juices containing sorbitol (prune, pear, apple) can increase stool frequency and water content as an alternative or adjunct approach 8. However, PEG remains the primary evidence-based osmotic laxative.
Pregnancy Considerations
PEG is safe during pregnancy 9. Osmotic laxatives like PEG and lactulose can be administered safely, though excessive fiber and lactulose may cause maternal bloating 9.
Key Clinical Pearls
- Dose titration is essential: Adjust based on response (target ≥3 bowel movements/week with no soiling) 3
- Higher initial doses work better for impaction: Don't underdose when clearing fecal impaction 5
- Long-term use is appropriate: Unlike the FDA label suggesting 7-day limits for OTC use, clinical evidence supports months-long therapy 6
- No need for dose escalation with growth: Children maintain effective symptom control on stable doses despite weight gain 6
- Treatment success definition: ≥3 complete spontaneous bowel movements per week with an increase of ≥1 from baseline 7
Avoid stimulant laxatives in children, as safety data are conflicting 9. PEG should be the first-line osmotic laxative choice over alternatives like lactulose, which may cause more bloating 9, 10.